{"entity":{"id":"inventisbio","kind":"company","name":"InventisBio","aka":["益方生物"],"tldr":"InventisBio developed garsorasib, one of the two KRAS G12C pills approved in China in 2024, and the third-generation EGFR inhibitor befotertinib.","summary":"InventisBio, based in Shanghai, founded in 2013 and listed as 688382.SS, developed garsorasib, one of the two KRAS G12C tablets approved in China in 2024, and the third-generation EGFR inhibitor befotertinib. Garsorasib, or D-1553, was approved in August 2024, befotertinib, or D-0316, was approved in 2023 through Betta Pharmaceuticals for EGFR-mutant non-small-cell lung cancer, and earlier programmes covered gout and oestrogen receptor degraders. OnCo links it to garsorasib and to Betta Pharmaceuticals. Whether a second domestic KRAS G12C inhibitor can differentiate from the other in the same market is the open question. Garsorasib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.inventisbio.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["garsorasib","in10018","d-0502"],"companies":["betta"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04585035","nct06166836","nct05379946"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.inventisbio.com/","ticker":"688382.SS","founded":2013,"investors":[],"funding":[]},"route":"/companies/inventisbio/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"d-0502","kind":"drug","name":"D-0502","route":"/drugs/d-0502/"},{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/"},{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"}],"company":[{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/"}],"trial":[{"id":"nct06954961","kind":"trial","name":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct06954961/"},{"id":"nct06166836","kind":"trial","name":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","route":"/trials/nct06166836/"},{"id":"nct05379946","kind":"trial","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","route":"/trials/nct05379946/"},{"id":"nct04585035","kind":"trial","name":"Study to Evaluate D-1553 in Subjects With Solid Tumors","route":"/trials/nct04585035/"}]}}